Enfuvirtide Acetate (T-20)
alias:Fuzeon
Sequentia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser
Cas No. : 159519-65-0
Formulae hypotheticae : C204H301N51O64
M. Pondus : 4492
Puritas (HPLC) : 98.0%min.
Aspectus : Alba ut off-album amorpho solidum
una immunditia (HPLC) : 0.5%max
Amino Acidum Compositio : ± X% speculationis
Peptide Content (N%) : ≥80.0%
Aqua Content (Carolus Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ESI) : Congruunt
Massa Libra : 95.0~105.0%
Gradus : Pharmaceutical Grade
Repono: Clausa, infra 2 ~ 8℃ conservatio
Usage : Curatio optionis pro aegris laborantibus HIV / SCDI.
Enfuvirtide est antiretroviralis medicamento in compositione justo pro curatione HIV-1/AIDS. Alligat primo heptad-repeat (HR1) in gp41 subunita involucri viralis glycoprotein et mutationes conformationales prohibet quae requiruntur ad fusione membranarum viralium et cellularum.. Operatur per turbationem HIV-1 machinae hypotheticae in ultimo gradu fusionis cum cellula scopo, ne infectae cellulis inficiuntur.
Enfuvirtide (INN) est HIV fusione inhibitor, prima novae classis medicamentorum antiretroviralium in compositione curationis HIV-1 infectio adhibita. Venales sub nomine commercii Fuzeon (Roche).
